04 September 2019
Visiongain has launched a new pharma report Cervical Cancer Treatment Market 2019-2029: By Type (SCC, Adenocarcinoma), by Product (Prevention, Treatment), by Treatment (Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy, Hormone Therapy), by End User (Cancer Diagnostics, Pharmacies) and by Region.
Global cervical cancer treatment market is anticipated to grow on account of rising cervical cancer incidences, growing investments from government and big giants for R&D in cancer research among others. The global cervical cancer treatment market is anticipated to grow at a lucrative CAGR of 5.2% and anticipated to reach USD 11.36 Billion by 2029.
Globally cervical cancer is the fourth most common cancer among women population accounting for an estimated 570,000 fresh cases and 311,000 deaths worldwide in 2018. The highest mortality and incidence rates are seen in African countries, where the rates are 7 to 10 times high as compared to North America, New Zealand, Australia and Western Asia. Also, it is estimated that without urgent scale up of services, the burden will account for almost 450,000 deaths by 2040. Lower-income nations will have the largest relative rise in the annual number of cervical cancer cases, exacerbating the present disparity. Almost 90% of fatalities in low-and middle-income nations (LMICs) are already occurring today. There is also proof that females from the poorest nations are less likely to benefit from timely prevention and detection and are more probable to die from cervical cancer than those from better socio-economic regions.
In most Western countries, cervical cancer is extremely preventable because there are screening tests and a vaccine available to avoid HPV infections. It is extremely treatable and linked with lengthy survival and excellent quality of life when cervical cancer is discovered prematurely.
Lack of knowledge of the techniques of diagnosis and treatment, elevated treatment costs, and adverse effects of cancer therapy can hinder market growth. In addition, the absence of targeted medicines with an enhanced clinical profile at decreased expenses and a convenient administration schedule is also probable to hinder market growth. However, increasing R&D spending on oncological illnesses in the foreseeable future offers a promising future for the worldwide market for cervical cancer treatment.
North America holds majority of market share followed by Europe and will continue to dominate in the future owing to increased disease prevalence, lifestyle changes, consumer awareness along with technological advancements in the diagnosis and treatment of oncological diseases. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period driven by improving economy and resultant emphasis on preventive healthcare. In China, the incidence and death rates of cervical cancer are also high, with 106,000 new cases reported and about 48,000 deaths last year. Also, Chinese researchers have developed a accurate and rapid screening model with the help artificial intelligence (AI) technologies to diagnose cervical cancer, a common and fatal disease among women population.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global single-cell genomics market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.
The comprehensive market report features companies such as Advaxis, Aetna Inc., ALLERGAN, Amgen Inc., AstraZeneca, BD, Biocon, Biocon Ltd., Bristol-MYERS SQUIBB, Eli Lilly & Company, F. Hoffmann-LA Roche Ltd, Genentech Inc., GlaxoSmithKline plc., Hologic, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., QIAGEN, Seimens Healthcare, Teva Pharmaceutical Industries Ltd. among other prominent players.
Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.